Endocannabinoid system

Last updated
3D model of 2-Arachidonoylglycerol, an endocannaboid 2-arachidonoylglycerol 3D BS.png
3D model of 2-Arachidonoylglycerol, an endocannaboid

The endocannabinoid system (ECS) is a biological system composed of endocannabinoids, which are endogenous lipid-based retrograde neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the vertebrate central nervous system (including the brain) and peripheral nervous system. [1] [2] The endocannabinoid system remains under preliminary research, but may be involved in regulating physiological and cognitive processes, including fertility, [3] pregnancy, [4] pre- and postnatal development, [5] [6] [7] various activity of immune system, [8] appetite, pain-sensation, mood, and memory, and in mediating the pharmacological effects of cannabis. [9] [10] The ECS plays an important role in multiple aspects of neural functions, including the control of movement and motor coordination, learning and memory, emotion and motivation, addictive-like behavior and pain modulation, among others. [11]

Contents

Two primary cannabinoid receptors have been identified: CB1, first cloned (or isolated) in 1990; and CB2, cloned in 1993. CB1 receptors are found predominantly in the brain and nervous system, as well as in peripheral organs and tissues, and are the main molecular target of the endogenous partial agonist, anandamide, as well as exogenous tetrahydrocannabinol, the most known active component of cannabis. Endocannabinoid 2-arachidonoylglycerol (2-AG), which was found to be two and three orders of magnitude more abundant in mammalian brain than anandamide, acts as a full agonist at both CB receptors. [12]

The endocannabinoid system is sometimes referred to as the endocannabinoidome or expanded endocannabinoid system. [13] [14] [15] [16]

Basic overview

The endocannabinoid system, broadly speaking, includes:

The neurons, neural pathways, and other cells where these molecules, enzymes, and one or both cannabinoid receptor types are all colocalized collectively comprise the endocannabinoid system.

The endocannabinoid system has been studied using genetic and pharmacological methods. These studies have revealed that cannabinoids act as neuromodulators [18] [19] [20] for a variety of processes, including motor learning, [21] appetite, [22] and pain sensation, [23] among other cognitive and physical processes. The localization of the CB1 receptor in the endocannabinoid system has a very large degree of overlap with the orexinergic projection system, which mediates many of the same functions, both physical and cognitive. [24] Moreover, CB1 is colocalized on orexin projection neurons in the lateral hypothalamus and many output structures of the orexin system, [24] [25] where the CB1 and orexin receptor 1 (OX1) receptors physically and functionally join to form the CB1–OX1 receptor heterodimer. [24] [26] [27]

Expression of receptors

Cannabinoid binding sites exist throughout the central and peripheral nervous systems. The two most relevant receptors for cannabinoids are the CB1 and CB2 receptors, which are expressed predominantly in the brain and immune system respectively. [28] Density of expression varies based on species and correlates with the efficacy that cannabinoids will have in modulating specific aspects of behavior related to the site of expression. For example, in rodents, the highest concentration of cannabinoid binding sites are in the basal ganglia and cerebellum, regions of the brain involved in the initiation and coordination of movement. [29] In humans, cannabinoid receptors exist in much lower concentration in these regions, which helps explain why cannabinoids possess a greater efficacy in altering rodent motor movements than they do in humans.

A recent analysis of cannabinoid binding in CB1 and CB2 receptor knockout mice found cannabinoid responsiveness even when these receptors were not being expressed, indicating that an additional binding receptor may be present in the brain. [29] Binding has been demonstrated by 2-arachidonoylglycerol (2-AG) on the TRPV1 receptor suggesting that this receptor may be a candidate for the established response. [30]

In addition to CB1 and CB2, certain orphan receptors are known to bind endocannabinoids as well, including GPR18, GPR55 (a regulator of neuroimmune function), and GPR119. CB1 has also been noted to form a functional human receptor heterodimer in orexin neurons with OX1, the CB1–OX1 receptor, which mediates feeding behavior and certain physical processes such as cannabinoid-induced pressor responses which are known to occur through signaling in the rostral ventrolateral medulla. [31] [32]

Endocannabinoid synthesis, release, and degradation

During neurotransmission, the pre-synaptic neuron releases neurotransmitters into the synaptic cleft which bind to cognate receptors expressed on the post-synaptic neuron. Based upon the interaction between the transmitter and receptor, neurotransmitters may trigger a variety of effects in the post-synaptic cell, such as excitation, inhibition, or the initiation of second messenger cascades. Based on the cell, these effects may result in the on-site synthesis of endogenous cannabinoids anandamide or 2-AG by a process that is not entirely clear, but results from an elevation in intracellular calcium. [28] Expression appears to be exclusive, so that both types of endocannabinoids are not co-synthesized. This exclusion is based on synthesis-specific channel activation: a recent study found that in the bed nucleus of the stria terminalis, calcium entry through voltage-sensitive calcium channels produced an L-type current resulting in 2-AG production, while activation of mGluR1/5 receptors triggered the synthesis of anandamide. [30]

Evidence suggests that the depolarization-induced influx of calcium into the post-synaptic neuron causes the activation of an enzyme called transacylase. This enzyme is suggested to catalyze the first step of endocannabinoid biosynthesis by converting phosphatidylethanolamine, a membrane-resident phospholipid, into N-acyl-phosphatidylethanolamine (NAPE). Experiments have shown that phospholipase D cleaves NAPE to yield anandamide. [33] [34] This process is mediated by bile acids. [35] [36] In NAPE-phospholipase D (NAPEPLD)-knockout mice, cleavage of NAPE is reduced in low calcium concentrations, but not abolished, suggesting multiple, distinct pathways are involved in anandamide synthesis. [37] The synthesis of 2-AG is less established and warrants further research.

Once released into the extracellular space by a putative endocannabinoid transporter, messengers are vulnerable to glial cell inactivation. Endocannabinoids are taken up by a transporter on the glial cell and degraded by fatty acid amide hydrolase (FAAH), which cleaves anandamide into arachidonic acid and ethanolamine or monoacylglycerol lipase (MAGL), and 2-AG into arachidonic acid and glycerol. [38] While arachidonic acid is a substrate for leukotriene and prostaglandin synthesis, it is unclear whether this degradative byproduct has unique functions in the central nervous system. [39] [40] Emerging data in the field also points to FAAH being expressed in postsynaptic neurons complementary to presynaptic neurons expressing cannabinoid receptors, supporting the conclusion that it is major contributor to the clearance and inactivation of anandamide and 2-AG after endocannabinoid reuptake. [29] A neuropharmacological study demonstrated that an inhibitor of FAAH (URB597) selectively increases anandamide levels in the brain of rodents and primates. Such approaches could lead to the development of new drugs with analgesic, anxiolytic-like and antidepressant-like effects, which are not accompanied by overt signs of abuse liability. [41]

Binding and intracellular effects

Cannabinoid receptors are G-protein coupled receptors located on the pre-synaptic membrane. While there have been some papers that have linked concurrent stimulation of dopamine and CB1 receptors to an acute rise in cyclic adenosine monophosphate (cAMP) production, it is generally accepted that CB1 activation via cannabinoids causes a decrease in cAMP concentration [42] by inhibition of adenylyl cyclase and a rise in the concentration of mitogen-activated protein kinase (MAP kinase). [17] [29] The relative potency of different cannabinoids in inhibition of adenylyl cyclase correlates with their varying efficacy in behavioral assays. This inhibition of cAMP is followed by phosphorylation and subsequent activation of not only a suite of MAP kinases (p38/p42/p44), but also the PI3/PKB and MEK/ERK pathway. [43] [44] Results from rat hippocampal gene chip data after acute administration of tetrahydrocannabinol (THC) showed an increase in the expression of transcripts encoding myelin basic protein, endoplasmic proteins, cytochrome oxidase, and two cell adhesion molecules: NCAM, and SC1; decreases in expression were seen in both calmodulin and ribosomal RNAs. [45] In addition, CB1 activation has been demonstrated to increase the activity of transcription factors like c-Fos and Krox-24. [44]

Binding and neuronal excitability

The molecular mechanisms of CB1-mediated changes to the membrane voltage have also been studied in detail. Cannabinoids reduce calcium influx by blocking the activity of voltage-dependent N-, P/Q- and L-type calcium channels. [46] [47] In addition to acting on calcium channels, activation of Gi/o and Gs, the two most commonly coupled G-proteins to cannabinoid receptors, has been shown to modulate potassium channel activity. Recent studies have found that CB1 activation specifically facilitates potassium ion flux through GIRKs, a family of potassium channels. [47] Immunohistochemistry experiments demonstrated that CB1 is co-localized with GIRK and Kv1.4 potassium channels, suggesting that these two may interact in physiological contexts. [48]

In the central nervous system, CB1 receptors influence neuronal excitability, reducing the incoming synaptic input. [49] This mechanism, known as presynaptic inhibition, occurs when a postsynaptic neuron releases endocannabinoids in retrograde transmission, which then bind to cannabinoid receptors on the presynaptic terminal. CB1 receptors then reduce the amount of neurotransmitter released, so that subsequent excitation in the presynaptic neuron results in diminished effects on the postsynaptic neuron. It is likely that presynaptic inhibition uses many of the same ion channel mechanisms listed above, although recent evidence has shown that CB1 receptors can also regulate neurotransmitter release by a non-ion channel mechanism, i.e. through Gi/o-mediated inhibition of adenylyl cyclase and protein kinase A. [50] Direct effects of CB1 receptors on membrane excitability have been reported, and strongly impact the firing of cortical neurons. [51] A series of behavioral experiments demonstrated that NMDAR, an ionotropic glutamate receptor, and the metabotropic glutamate receptors (mGluRs) work in concert with CB1 to induce analgesia in mice, although the mechanism underlying this effect is unclear.[ citation needed ]

Potential functions

Memory

Mice treated with tetrahydrocannabinol (THC) show suppression of long-term potentiation in the hippocampus, a process that is essential for the formation and storage of long-term memory. [52] These results may concur with anecdotal evidence suggesting that smoking cannabis impairs short-term memory. [53] Consistent with this finding, mice without the CB1 receptor show enhanced memory and long-term potentiation indicating that the endocannabinoid system may play a pivotal role in the extinction of old memories. One study found that the high-dose treatment of rats with the synthetic cannabinoid HU-210 over several weeks resulted in stimulation of neural growth in the rats' hippocampus region, a part of the limbic system playing a part in the formation of declarative and spatial memories, but did not investigate the effects on short-term or long-term memory. [54] Taken together, these findings suggest that the effects of endocannabinoids on the various brain networks involved in learning and memory may vary.

Role in hippocampal neurogenesis

In the adult brain, the endocannabinoid system facilitates the neurogenesis of hippocampal granule cells. [54] [55] In the subgranular zone of the dentate gyrus, multipotent neural progenitors (NP) give rise to daughter cells that, over the course of several weeks, mature into granule cells whose axons project to and synapse onto dendrites on the CA3 region. [56] NPs in the hippocampus have been shown to possess fatty acid amide hydrolase (FAAH) and express CB1 and utilize 2-AG. [55] Intriguingly, CB1 activation by endogenous or exogenous cannabinoids promote NP proliferation and differentiation; this activation is absent in CB1 knockouts and abolished in the presence of antagonist. [54] [55]

Induction of synaptic depression

Endocannabinoids are known to influence synaptic plasticity, and are in particular thought to mediate long-term depression (LTD, which refers to neuronal firing, not psychological depression). Short-term depression (STD) has also been described (see the next paragraph). First reported in the striatum, [57] this system is known to function in several other brain structures such as the nucleus accumbens, amygdala, hippocampus, cerebral cortex, cerebellum, ventral tegmental area (VTA), brain stem, and superior colliculus. [58] Typically, these retrograde transmitters are released by the postsynaptic neuron and induce synaptic depression by activating the presynaptic CB1 receptors. [58]

It has further been suggested that different endocannabinoids, i.e. 2-AG and anandamide, might mediate different forms of synaptic depression through different mechanisms. [30] The study conducted with the bed nucleus of the stria terminalis found that the endurance of the depressant effects was mediated by two different signaling pathways based on the type of receptor activated. 2-AG was found to act on presynaptic CB1 receptors to mediate retrograde STD following activation of L-type calcium channeles, while anandamide was synthesized after mGluR5 activation and triggered autocrine signalling onto postsynapic TRPV1 receptors that induced LTD. [30] These findings provide the brain a direct mechanism to selectively inhibit neuronal excitability over variable time scales. By selectively internalizing different receptors, the brain may limit the production of specific endocannabinoids to favor a time scale in accordance with its needs.

Appetite

Evidence for the role of the endocannabinoid system in food-seeking behavior comes from a variety of cannabinoid studies. Emerging data suggests that THC acts via CB1 receptors in the hypothalamic nuclei to directly increase appetite. [59] It is thought that hypothalamic neurons tonically produce endocannabinoids that work to tightly regulate hunger. The amount of endocannabinoids produced is inversely correlated with the amount of leptin in the blood. [60] For example, mice without leptin not only become massively obese but express abnormally high levels of hypothalamic endocannabinoids as a compensatory mechanism. [22] Similarly, when these mice were treated with an endocannabinoid inverse agonists, such as rimonabant, food intake was reduced. [22] When the CB1 receptor is knocked out in mice, these animals tend to be leaner and less hungry than wild-type mice. A related study examined the effect of THC on the hedonic (pleasure) value of food and found enhanced dopamine release in the nucleus accumbens and increased pleasure-related behavior after administration of a sucrose solution. [61] A related study found that endocannabinoids affect taste perception in taste cells. [62] In taste cells, endocannabinoids were shown to selectively enhance the strength of neural signaling for sweet tastes, whereas leptin decreased the strength of this same response. While there is need for more research, these results suggest that cannabinoid activity in the hypothalamus and nucleus accumbens is related to appetitive, food-seeking behavior. [59]

Energy balance and metabolism

The endocannabinoid system has been shown to have a homeostatic role by controlling several metabolic functions, such as energy storage and nutrient transport. It acts on peripheral tissues such as adipocytes, hepatocytes, the gastrointestinal tract, the skeletal muscles and the endocrine pancreas. It has also been implied in modulating insulin sensitivity. Through all of this, the endocannabinoid system may play a role in clinical conditions, such as obesity, diabetes, and atherosclerosis, which may also give it a cardiovascular role. [63]

Stress response

While the secretion of glucocorticoids in response to stressful stimuli is an adaptive response necessary for an organism to respond appropriately to a stressor, persistent secretion may be harmful. The endocannabinoid system has been implicated in the habituation of the hypothalamic-pituitary-adrenal axis (HPA axis) to repeated exposure to restraint stress. Studies have demonstrated differential synthesis of anandamide and 2-AG during tonic stress. A decrease of anandamide was found along the axis that contributed to basal hypersecretion of corticosterone; in contrast, an increase of 2-AG was found in the amygdala after repeated stress, which was negatively correlated to magnitude of the corticosterone response. All effects were abolished by the CB1 antagonist AM251, supporting the conclusion that these effects were cannabinoid-receptor dependent. [64] These findings show that anandamide and 2-AG divergently regulate the HPA axis response to stress: while habituation of the stress-induced HPA axis via 2-AG prevents excessive secretion of glucocorticoids to non-threatening stimuli, the increase of basal corticosterone secretion resulting from decreased anandamide allows for a facilitated response of the HPA axis to novel stimuli.

Exploration, social behavior, and anxiety

These contrasting effects reveal the importance of the endocannabinoid system in regulating anxiety-dependent behavior. Results suggest that glutamatergic cannabinoid receptors are not only responsible for mediating aggression, but produce an anxiolytic-like function by inhibiting excessive arousal: excessive excitation produces anxiety that limited the mice from exploring both animate and inanimate objects. In contrast, GABAergic neurons appear to control an anxiogenic-like function by limiting inhibitory transmitter release. Taken together, these two sets of neurons appear to help regulate the organism's overall sense of arousal during novel situations. [65]

Immune system

In laboratory experiments, activation of cannabinoid receptors had an effect on the activation of GTPases in macrophages, neutrophils, and bone marrow cells. These receptors have also been implicated in the migration of B cells into the marginal zone and the regulation of IgM levels. [66]

Female reproduction

The developing embryo expresses cannabinoid receptors early in development that are responsive to anandamide secreted in the uterus. This signaling is important in regulating the timing of embryonic implantation and uterine receptivity. In mice, it has been shown that anandamide modulates the probability of implantation to the uterine wall. For example, in humans, the likelihood of miscarriage increases if uterine anandamide levels are too high or low. [67] These results suggest that intake of exogenous cannabinoids (e.g. cannabis) can decrease the likelihood for pregnancy for women with high anandamide levels, and alternatively, it can increase the likelihood for pregnancy in women whose anandamide levels were too low. [68] [69]

Autonomic nervous system

Peripheral expression of cannabinoid receptors led researchers to investigate the role of cannabinoids in the autonomic nervous system. Research found that the CB1 receptor is expressed presynaptically by motor neurons that innervate visceral organs. Cannabinoid-mediated inhibition of electric potentials results in a reduction in noradrenaline release from sympathetic nervous system nerves. Other studies have found similar effects in endocannabinoid regulation of intestinal motility, including the innervation of smooth muscles associated with the digestive, urinary, and reproductive systems. [29]

Analgesia

At the spinal cord, cannabinoids suppress noxious-stimulus-evoked responses of neurons in the dorsal horn, possibly by modulating descending noradrenaline input from the brainstem. [29] As many of these fibers are primarily GABAergic, cannabinoid stimulation in the spinal column results in disinhibition that should increase noradrenaline release and attenuation of noxious-stimuli-processing in the periphery and dorsal root ganglion.

The endocannabinoid most researched in pain is palmitoylethanolamide. Palmitoylethanolamide is a fatty amine related to anandamide, but saturated and although initially it was thought that palmitoylethanolamide would bind to the CB1 and the CB2 receptor, later it was found that the most important receptors are the PPAR-alpha receptor, the TRPV receptor and the GPR55 receptor. Palmitoylethanolamide has been evaluated for its analgesic actions in a great variety of pain indications [70] and found to be safe and effective.

Modulation of the endocannabinoid system by metabolism to N-arachidinoyl-phenolamine (AM404), an endogenous cannabinoid neurotransmitter, has been discovered to be one mechanism [71] for analgesia by acetaminophen (paracetamol).

Endocannabinoids are involved in placebo induced analgesia responses. [72]

Thermoregulation

Anandamide and N-arachidonoyl dopamine (NADA) have been shown to act on temperature-sensing TRPV1 channels, which are involved in thermoregulation. [73] TRPV1 is activated by the exogenous ligand capsaicin, the active component of chili peppers, which is structurally similar to endocannabinoids. NADA activates the TRPV1 channel with an EC50 of approximately of 50 nM.[ clarify ] The high potency makes it the putative endogenous TRPV1 agonist. [74] Anandamide has also been found to activate TRPV1 on sensory neuron terminals, and subsequently cause vasodilation. [29] TRPV1 may also be activated by methanandamide and arachidonyl-2'-chloroethylamide (ACEA). [17]

Sleep

Increased endocannabinoid signaling within the central nervous system promotes sleep-inducing effects. Intercerebroventricular administration of anandamide in rats has been shown to decrease wakefulness and increase slow-wave sleep and REM sleep. [75] Administration of anandamide into the basal forebrain of rats has also been shown to increase levels of adenosine, which plays a role in promoting sleep and suppressing arousal. [76] REM sleep deprivation in rats has been demonstrated to increase CB1 receptor expression in the central nervous system. [77] Furthermore, anandamide levels possess a circadian rhythm in the rat, with levels being higher in the light phase of the day, which is when rats are usually asleep or less active, since they are nocturnal. [78]

Physical exercise

The endocannabinoid system is also involved in mediating some of the physiological and cognitive effects of voluntary physical exercise in humans and other animals, such as contributing to exercise-induced euphoria as well as modulating locomotor activity and motivational salience for rewards. [79] [80] In humans, the plasma concentration of certain endocannabinoids (i.e., anandamide) have been found to rise during physical activity; [79] [80] since endocannabinoids can effectively penetrate the blood–brain barrier, it has been suggested that anandamide, along with other euphoriant neurochemicals, contributes to the development of exercise-induced euphoria in humans, a state colloquially referred to as a runner's high. [79] [80]

Cannabinoids in plants

The endocannabinoid system is by molecular phylogenetic distribution of apparently ancient lipids in the plant kingdom, indicative of biosynthetic plasticity and potential physiological roles of endocannabinoid-like lipids in plants, [81] and detection of arachidonic acid (AA) indicates chemotaxonomic connections between monophyletic groups with common ancestor dates to around 500 million years ago (Cambrian). The phylogenetic distribution of these lipids may be a consequence of interactions/adaptations to the surrounding conditions such as chemical plant-pollinator interactions, communication and defense mechanisms. The two novel EC-like molecules derived from the eicosatetraenoic acid juniperonic acid, an omega-3 structural isomer of AA, namely juniperoyl ethanolamide and 2-juniperoyl glycerol (1/2-AG) in gymnosperms, lycophytes and few monilophytes, show AA is an evolutionarily conserved signalling molecule that acts in plants in response to stress similar to that in animal systems. [82] The endocannabinoid Docosatetraenoylethanolamide has been found in Tropaeolum tuberosum (Mashua) and Leonotis leonurus (Lion's tail) [83] Maca contains several N-benzylamides referred to as "macamides" that are structurally related to endocannabinoids such as the N-Benzyl analog of Oleamide. [84] Echinacea contains alkylamides structurally related to endocannabinoids. [85]

Cannabinoids in Cyanobacterium

Serinolamide A is a cannabinoid structurally related to endocannabinoids found in cyanobacteria such as Lyngbya majuscula and other species in the Oscillatoria family.

Endocannabinoid articles

See also

Related Research Articles

<span class="mw-page-title-main">Anandamide</span> Chemical compound (fatty acid neurotransmitter)

Anandamide (ANA), also known as N-arachidonoylethanolamine (AEA), an N-acylethanolamine (NAE), is a fatty acid neurotransmitter. Anandamide was the first endocannabinoid to be discovered: it participates in the body's endocannabinoid system by binding to cannabinoid receptors, the same receptors that the psychoactive compound THC in cannabis acts on. Anandamide is found in nearly all tissues in a wide range of animals. Anandamide has also been found in plants, including small amounts in chocolate. The name 'anandamide' is taken from the Sanskrit word ananda, which means "joy, bliss, delight", plus amide.

<span class="mw-page-title-main">Cannabinoid</span> Compounds found in cannabis

Cannabinoids are several structural classes of compounds found in the cannabis plant primarily and most animal organisms or as synthetic compounds. The most notable cannabinoid is the phytocannabinoid tetrahydrocannabinol (THC) (delta-9-THC), the primary psychoactive compound in cannabis. Cannabidiol (CBD) is also a major constituent of temperate cannabis plants and a minor constituent in tropical varieties. At least 113 distinct phytocannabinoids have been isolated from cannabis, although only four have been demonstrated to have a biogenetic origin. It was reported in 2020 that phytocannabinoids can be found in other plants such as rhododendron, licorice and liverwort, and earlier in Echinacea.

<span class="mw-page-title-main">Orexin</span> Neuropeptide that regulates arousal, wakefulness, and appetite.

Orexin, also known as hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite. The most common form of narcolepsy, type 1, in which the individual experiences brief losses of muscle tone, is caused by a lack of orexin in the brain due to destruction of the cells that produce it. It exists in the forms of orexin-A and orexin-B.

<span class="mw-page-title-main">Cannabinoid receptor</span> Group of receptors to cannabinoid compounds

Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system of vertebrates– a class of cell membrane receptors in the G protein-coupled receptor superfamily. As is typical of G protein-coupled receptors, the cannabinoid receptors contain seven transmembrane spanning domains. Cannabinoid receptors are activated by three major groups of ligands: endocannabinoids; phytocannabinoids ; and synthetic cannabinoids. All endocannabinoids and phytocannabinoids are lipophilic.

<span class="mw-page-title-main">Dopaminergic pathways</span> Projection neurons in the brain that synthesize and release dopamine

Dopaminergic pathways in the human brain are involved in both physiological and behavioral processes including movement, cognition, executive functions, reward, motivation, and neuroendocrine control. Each pathway is a set of projection neurons, consisting of individual dopaminergic neurons.

<span class="mw-page-title-main">Cannabinol</span> Naturally-occurring cannabinoid

Cannabinol (CBN) is a mildly psychoactive cannabinoid that acts as a low affinity partial agonist at both CB1 and CB2 receptors. This activity at CB1 and CB2 receptors constitutes interaction of CBN with the endocannabinoid system (ECS).

<span class="mw-page-title-main">Neurotransmission</span> Impulse transmission between neurons

Neurotransmission is the process by which signaling molecules called neurotransmitters are released by the axon terminal of a neuron, and bind to and react with the receptors on the dendrites of another neuron a short distance away. A similar process occurs in retrograde neurotransmission, where the dendrites of the postsynaptic neuron release retrograde neurotransmitters that signal through receptors that are located on the axon terminal of the presynaptic neuron, mainly at GABAergic and glutamatergic synapses.

Depolarization-induced suppression of inhibition is the classical and original electrophysiological example of endocannabinoid function in the central nervous system. Prior to the demonstration that depolarization-induced suppression of inhibition was dependent on the cannabinoid CB1 receptor function, there was no way of producing an in vitro endocannabinoid mediated effect.

<span class="mw-page-title-main">Lateral hypothalamus</span>

The lateral hypothalamus (LH), also called the lateral hypothalamic area (LHA), contains the primary orexinergic nucleus within the hypothalamus that widely projects throughout the nervous system; this system of neurons mediates an array of cognitive and physical processes, such as promoting feeding behavior and arousal, reducing pain perception, and regulating body temperature, digestive functions, and blood pressure, among many others. Clinically significant disorders that involve dysfunctions of the orexinergic projection system include narcolepsy, motility disorders or functional gastrointestinal disorders involving visceral hypersensitivity, and eating disorders.

<span class="mw-page-title-main">2-Arachidonoylglycerol</span> Chemical compound

2-Arachidonoylglycerol (2-AG) is an endocannabinoid, an endogenous agonist of the CB1 receptor and the primary endogenous ligand for the CB2 receptor. It is an ester formed from the omega-6 fatty acid arachidonic acid and glycerol. It is present at relatively high levels in the central nervous system, with cannabinoid neuromodulatory effects. It has been found in maternal bovine and human milk. The chemical was first described in 1994–1995, although it had been discovered some time before that. The activities of phospholipase C (PLC) and diacylglycerol lipase (DAGL) mediate its formation. 2-AG is synthesized from arachidonic acid-containing diacylglycerol (DAG).

<span class="mw-page-title-main">TRPV1</span> Human protein for regulating body temperature

The transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the capsaicin receptor and the vanilloid receptor 1, is a protein that, in humans, is encoded by the TRPV1 gene. It was the first isolated member of the transient receptor potential vanilloid receptor proteins that in turn are a sub-family of the transient receptor potential protein group. This protein is a member of the TRPV group of transient receptor potential family of ion channels. Fatty acid metabolites with affinity for this receptor are produced by cyanobacteria, which diverged from eukaryotes at least 2000 million years ago (MYA). The function of TRPV1 is detection and regulation of body temperature. In addition, TRPV1 provides a sensation of scalding heat and pain (nociception). In primary afferent sensory neurons, it cooperates with TRPA1 to mediate the detection of noxious environmental stimuli.

<span class="mw-page-title-main">AM404</span> Active metabolite of paracetamol

AM404, also known as N-arachidonoylphenolamine, is an active metabolite of paracetamol (acetaminophen), responsible for all or part of its analgesic action and anticonvulsant effects. Chemically, it is the amide formed from 4-aminophenol and arachidonic acid.

<span class="mw-page-title-main">NAGly receptor</span> Protein-coding gene in the species Homo sapiens

N-Arachidonyl glycine receptor, also known as G protein-coupled receptor 18 (GPR18), is a protein that in humans is encoded by the GPR18 gene. Along with the other previously "orphan" receptors GPR55 and GPR119, GPR18 has been found to be a receptor for endogenous lipid neurotransmitters, several of which also bind to cannabinoid receptors. It has been found to be involved in the regulation of intraocular pressure.

<span class="mw-page-title-main">Cannabinoid receptor 1</span> Mammalian protein found in Homo sapiens

Cannabinoid receptor 1 (CB1), is a G protein-coupled cannabinoid receptor that in humans is encoded by the CNR1 gene. The human CB1 receptor is expressed in the peripheral nervous system and central nervous system. It is activated by endocannabinoids, a group of retrograde neurotransmitters that include anandamide and 2-arachidonoylglycerol (2-AG); plant phytocannabinoids, such as docosatetraenoylethanolamide found in wild daga, the compound THC which is an active constituent of the psychoactive drug cannabis; and synthetic analogs of THC. CB1 is antagonized by the phytocannabinoid tetrahydrocannabivarin (THCV).

<span class="mw-page-title-main">Cannabinoid receptor 2</span> Mammalian protein found in Homo sapiens

The cannabinoid receptor 2(CB2), is a G protein-coupled receptor from the cannabinoid receptor family that in humans is encoded by the CNR2 gene. It is closely related to the cannabinoid receptor 1 (CB1), which is largely responsible for the efficacy of endocannabinoid-mediated presynaptic-inhibition, the psychoactive properties of tetrahydrocannabinol (THC), the active agent in cannabis, and other phytocannabinoids. The principal endogenous ligand for the CB2 receptor is 2-Arachidonoylglycerol (2-AG).

<i>N</i>-Arachidonoyl dopamine Chemical compound

N-Arachidonoyl dopamine (NADA) is an endocannabinoid that acts as an agonist of the CB1 receptor and the transient receptor potential V1 (TRPV1) ion channel. NADA was first described as a putative endocannabinoid (agonist for the CB1 receptor) in 2000 and was subsequently identified as an endovanilloid (agonist for TRPV1) in 2002. NADA is an endogenous arachidonic acid based lipid found in the brain of rats, with especially high concentrations in the hippocampus, cerebellum, and striatum. It activates the TRPV1 channel with an EC50 of approximately of 50 nM which makes it the putative endogenous TRPV1 agonist.

<i>N</i>-Acylethanolamine Class of chemical compounds

An N-acylethanolamine (NAE) is a type of fatty acid amide where one of several types of acyl groups is linked to the nitrogen atom of ethanolamine, and highly metabolic formed by intake of essential fatty acids through diet by 20:4, n-6 and 22:6, n-3 fatty acids, and when the body is physically and psychologically active,. The endocannabinoid signaling system (ECS) is the major pathway by which NAEs exerts its physiological effects in animal cells with similarities in plants, and the metabolism of NAEs is an integral part of the ECS, a very ancient signaling system, being clearly present from the divergence of the protostomian/deuterostomian, and even further back in time, to the very beginning of bacteria, the oldest organisms on Earth known to express phosphatidylethanolamine, the precursor to endocannabinoids, in their cytoplasmic membranes. Fatty acid metabolites with affinity for CB receptors are produced by cyanobacteria, which diverged from eukaryotes at least 2000 million years ago (MYA), by brown algae which diverged about 1500 MYA, by sponges, which diverged from eumetazoans about 930 MYA, and a lineages that predate the evolution of CB receptors, as CB1 – CB2 duplication event may have occurred prior to the lophotrochozoan-deuterostome divergence 590 MYA. Fatty acid amide hydrolase (FAAH) evolved relatively recently, either after the evolution of fish 400 MYA, or after the appearance of mammals 300 MYA, but after the appearance of vertebrates. Linking FAAH, vanilloid receptors (VR1) and anandamide implies a coupling among the remaining ‘‘older’’ parts of the endocannabinoid system, monoglyceride lipase (MGL), CB receptors, that evolved prior to the metazoan-bilaterian divergence, but were secondarily lost in the Ecdysozoa, and 2-Arachidonoylglycerol (2-AG).

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide, and lipid modulator PEA has been studied in in vitro and in vivo systems using exogenously added or dosed compound; there is evidence that it binds to a nuclear receptor, through which it exerts a variety of biological effects, some related to chronic inflammation and pain.

RVD-Hpα (pepcan-12) is an endogenous neuropeptide found in human and mammalian brain, which was originally proposed to act as a selective agonist for the CB1 cannabinoid receptor. It is a 12-amino acid polypeptide having the amino acid sequence Arg-Val-Asp-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His and is an N-terminal extended form of hemopressin, a 9-AA polypeptide derived from the α1 subunit of hemoglobin which has previously been shown to act as a CB1 inverse agonist. All three polypeptides have been isolated from various mammalian species, with RVD-Hpα being one of the more abundant neuropeptides expressed in mouse brain, and these neuropeptides represent a new avenue for cannabinoid research distinct from the previously known endogenous lipid-derived cannabinoid agonists such as anandamide. Recently it was shown that RVD-Hpα (also called Pepcan-12) is a potent negative allosteric modulator at CB1 receptors, together with other newly described N-terminally extended peptides (pepcans).

<i>N</i>-Acylamides

N-acyl amides are a general class of endogenous fatty acid compounds characterized by a fatty acyl group linked to a primary amine metabolite by an amide bond. Broadly speaking, N-acyl amides fall into several categories: amino acid conjugates, neurotransmitter conjugates, ethanolamine conjugates, and taurine conjugates. N-acyl amides have pleiotropic signaling functions in physiology, including in cardiovascular function, metabolic homeostasis, memory, cognition, pain, motor control and others. Initial attention focused on N-acyl amides present in mammalian organisms, however recently lipid signaling systems consisting of N-acyl amides have also been found to be present in invertebrates, such as Drosophila melanogaster. N-acyl amides play important roles in many biochemical pathways involved in a variety of physiological and pathological processes, as well as the metabolic enzymes, transporters, and receptors that regulate their signaling.

References

  1. ↑ Freitas HR, Ferreira GD, Trevenzoli IH, Oliveira KJ, de Melo Reis RA (November 2017). "Fatty Acids, Antioxidants and Physical Activity in Brain Aging". Nutrients. 9 (11): 1263. doi: 10.3390/nu9111263 . PMC   5707735 . PMID   29156608.
  2. ↑ Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA (December 2018). "Polyunsaturated fatty acids and endocannabinoids in health and disease". Nutritional Neuroscience. 21 (10): 695–714. doi:10.1080/1028415X.2017.1347373. PMID   28686542. S2CID   40659630.
  3. ↑ Klein C, Hill MN, Chang SC, Hillard CJ, Gorzalka BB (June 2012). "Circulating endocannabinoid concentrations and sexual arousal in women". The Journal of Sexual Medicine. 9 (6): 1588–601. doi:10.1111/j.1743-6109.2012.02708.x. PMC   3856894 . PMID   22462722.
  4. ↑ Wang H, Xie H, Dey SK (June 2006). "Endocannabinoid signaling directs periimplantation events". The AAPS Journal. 8 (2): E425-32. doi:10.1007/BF02854916. PMC   3231559 . PMID   16808046.
  5. ↑ Freitas HR, Isaac AR, Silva TM, Diniz GO, Dos Santos Dabdab Y, Bockmann EC, et al. (September 2019). "Cannabinoids Induce Cell Death and Promote P2X7 Receptor Signaling in Retinal Glial Progenitors in Culture". Molecular Neurobiology. 56 (9): 6472–6486. doi:10.1007/s12035-019-1537-y. PMID   30838518. S2CID   71143662.
  6. ↑ Freitas HR, Reis RA, Ventura AL, França GR (December 2019). "Interaction between cannabinoid and nucleotide systems as a new mechanism of signaling in retinal cell death". Neural Regeneration Research. 14 (12): 2093–2094. doi: 10.4103/1673-5374.262585 . PMC   6788250 . PMID   31397346.
  7. ↑ Fride E (October 2004). "The endocannabinoid-CB(1) receptor system in pre- and postnatal life". European Journal of Pharmacology. SPECIAL CELEBRATORY VOLUME 500 Dedicated to Professor David de Wied Honorary and Founding Editor. 500 (1–3): 289–97. doi:10.1016/j.ejphar.2004.07.033. PMID   15464041.
  8. ↑ Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P (August 2009). "Endocannabinoids and immune regulation". Pharmacological Research. 60 (2): 85–92. doi:10.1016/j.phrs.2009.03.019. PMC   3044336 . PMID   19428268.
  9. ↑ Aizpurua-Olaizola O, Elezgarai I, Rico-Barrio I, Zarandona I, Etxebarria N, Usobiaga A (January 2017). "Targeting the endocannabinoid system: future therapeutic strategies". Drug Discovery Today. 22 (1): 105–110. doi:10.1016/j.drudis.2016.08.005. PMID   27554802. S2CID   3460960.
  10. ↑ Donvito G, Nass SR, Wilkerson JL, Curry ZA, Schurman LD, Kinsey SG, Lichtman AH (January 2018). "The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain". Neuropsychopharmacology. 43 (1): 52–79. doi:10.1038/npp.2017.204. PMC   5719110 . PMID   28857069.
  11. ↑ de Melo Reis RA, Isaac AR, Freitas HR, de Almeida MM, Schuck PF, Ferreira GC, et al. (2021). "Quality of Life and a Surveillant Endocannabinoid System". Frontiers in Neuroscience. 15: 747229. doi: 10.3389/fnins.2021.747229 . PMC   8581450 . PMID   34776851.
  12. ↑ Baggelaar MP, Maccarrone M, van der Stelt M (July 2018). "2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain". Progress in Lipid Research. 71: 1–17. doi: 10.1016/j.plipres.2018.05.002 . hdl: 1887/67627 . PMID   29751000.
  13. ↑ Di Marzo, Vincenzo (30 September 2020). "The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders". Dialogues in Clinical Neuroscience. 22 (3): 259–269. doi:10.31887/DCNS.2020.22.3/vdimarzo. ISSN   1958-5969. PMC   7605024 . PMID   33162769.
  14. ↑ Di Marzo, Vincenzo (19 September 2014). The Endocannabinoidome: The World of Endocannabinoids and Related Mediators. Elsevier Science. ISBN   9780124201262.
  15. ↑ Di Marzo, Vincenzo; Piscitelli, Fabiana (October 2015). "The Endocannabinoid System and its Modulation by Phytocannabinoids". Neurotherapeutics. 12 (4): 692–698. doi:10.1007/s13311-015-0374-6. ISSN   1933-7213. PMC   4604172 . PMID   26271952.
  16. ↑ Muller, Chanté; Morales, Paula; Reggio, Patricia H. (2019). "Cannabinoid Ligands Targeting TRP Channels". Frontiers in Molecular Neuroscience. 11: 487. doi: 10.3389/fnmol.2018.00487 . ISSN   1662-5099. PMC   6340993 . PMID   30697147.
  17. 1 2 3 Pertwee RG (April 2006). "The pharmacology of cannabinoid receptors and their ligands: an overview". International Journal of Obesity. 30 (Suppl 1): S13–8. doi: 10.1038/sj.ijo.0803272 . PMID   16570099.
  18. ↑ Fortin DA, Levine ES (2007). "Differential effects of endocannabinoids on glutamatergic and GABAergic inputs to layer 5 pyramidal neurons". Cerebral Cortex. 17 (1): 163–74. doi: 10.1093/cercor/bhj133 . PMID   16467564.
  19. ↑ Good CH (2007). "Endocannabinoid-dependent regulation of feedforward inhibition in cerebellar Purkinje cells". Journal of Neuroscience. 27 (1): 1–3. doi:10.1523/JNEUROSCI.4842-06.2007. PMC   6672293 . PMID   17205618.
  20. ↑ Hashimotodani Y, Ohno-Shosaku T, Kano M (2007). "Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus". Journal of Neuroscience. 27 (5): 1211–9. doi:10.1523/JNEUROSCI.4159-06.2007. PMC   6673197 . PMID   17267577.
  21. ↑ Kishimoto Y, Kano M (2006). "Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning". Journal of Neuroscience. 26 (34): 8829–37. doi:10.1523/JNEUROSCI.1236-06.2006. PMC   6674369 . PMID   16928872.
  22. 1 2 3 Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (April 2001). "Leptin-regulated endocannabinoids are involved in maintaining food intake". Nature. 410 (6830): 822–5. Bibcode:2001Natur.410..822D. doi:10.1038/35071088. PMID   11298451. S2CID   4350552.
  23. ↑ Cravatt BF, et al. (July 2001). "Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase". Proceedings of the National Academy of Sciences. 98 (16): 9371–6. Bibcode:2001PNAS...98.9371C. doi: 10.1073/pnas.161191698 . JSTOR   3056353. PMC   55427 . PMID   11470906.
  24. 1 2 3 Flores A, Maldonado R, Berrendero F (2013). "Cannabinoid-hypocretin cross-talk in the central nervous system: what we know so far". Frontiers in Neuroscience. 7: 256. doi: 10.3389/fnins.2013.00256 . PMC   3868890 . PMID   24391536. Direct CB1-HcrtR1 interaction was first proposed in 2003 (Hilairet et al., 2003). Indeed, a 100-fold increase in the potency of hypocretin-1 to activate the ERK signaling was observed when CB1 and HcrtR1 were co-expressed ... In this study, a higher potency of hypocretin-1 to regulate CB1-HcrtR1 heteromer compared with the HcrtR1-HcrtR1 homomer was reported (Ward et al., 2011b). These data provide unambiguous identification of CB1-HcrtR1 heteromerization, which has a substantial functional impact. ... The existence of a cross-talk between the hypocretinergic and endocannabinoid systems is strongly supported by their partially overlapping anatomical distribution and common role in several physiological and pathological processes. However, little is known about the mechanisms underlying this interaction.
     • Figure 1: Schematic of brain CB1 expression and orexinergic neurons expressing OX1 or OX2
     • Figure 2: Synaptic signaling mechanisms in cannabinoid and orexin systems
     • Figure 3: Schematic of brain pathways involved in food intake
  25. ↑ Watkins BA, Kim J (2014). "The endocannabinoid system: helps to direct eating behavior and macronutrient metabolism". Frontiers in Psychology. 5: 1506. doi: 10.3389/fpsyg.2014.01506 . PMC   4285050 . PMID   25610411. CB1 is present in neurons of the enteric nervous system and in sensory terminals of vagal and spinal neurons in the gastrointestinal tract (Massa et al., 2005). Activation of CB1 is shown to modulate nutrient processing, such as gastric secretion, gastric emptying, and intestinal motility. ... CB1 is shown to co-localize with the food intake inhibiting neuropeptide, corticotrophin-releasing hormone, in the paraventricular nucleus of the hypothalamus, and with the two orexigenic peptides, melanin-concentrating hormone in the lateral hypothalamus and with pre-pro-orexin in the ventromedial hypothalamus (Inui, 1999; Horvath, 2003). CB1 knockout mice showed higher levels of CRH mRNA, suggesting that hypothalamic EC receptors are involved in energy balance and may be able to mediate food intake (Cota et al., 2003). ... The ECS works through many anorexigenic and orexigenic pathways where ghrelin, leptin, adiponectin, endogenous opioids, and corticotropin-releasing hormones are involved (Viveros et al., 2008).
  26. ↑ Thompson MD, Xhaard H, Sakurai T, Rainero I, Kukkonen JP (2014). "OX1 and OX2 orexin/hypocretin receptor pharmacogenetics". Frontiers in Neuroscience. 8: 57. doi: 10.3389/fnins.2014.00057 . PMC   4018553 . PMID   24834023. OX1–CB1 dimerization was suggested to strongly potentiate orexin receptor signaling, but a likely explanation for the signal potentiation is, instead, offered by the ability of OX1 receptor signaling to produce 2-arachidonoyl glycerol, a CB1 receptor ligand, and a subsequent co-signaling of the receptors (Haj-Dahmane and Shen, 2005; Turunen et al., 2012; Jäntti et al., 2013). However, this does not preclude dimerization.
  27. ↑ Jäntti MH, Mandrika I, Kukkonen JP (2014). "Human orexin/hypocretin receptors form constitutive homo- and heteromeric complexes with each other and with human CB1 cannabinoid receptors". Biochemical and Biophysical Research Communications. 445 (2): 486–90. doi:10.1016/j.bbrc.2014.02.026. PMID   24530395. Orexin receptor subtypes readily formed homo- and hetero(di)mers, as suggested by significant BRET signals. CB1 receptors formed homodimers, and they also heterodimerized with both orexin receptors. ... In conclusion, orexin receptors have a significant propensity to make homo- and heterodi-/oligomeric complexes. However, it is unclear whether this affects their signaling. As orexin receptors efficiently signal via endocannabinoid production to CB1 receptors, dimerization could be an effective way of forming signal complexes with optimal cannabinoid concentrations available for cannabinoid receptors.
  28. 1 2 Pertwee RG (January 2008). "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin". British Journal of Pharmacology. 153 (2): 199–215. doi:10.1038/sj.bjp.0707442. PMC   2219532 . PMID   17828291.
  29. 1 2 3 4 5 6 7 Elphick MR, Egertová M (March 2001). "The neurobiology and evolution of cannabinoid signalling". Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. 356 (1407): 381–408. doi:10.1098/rstb.2000.0787. PMC   1088434 . PMID   11316486.
  30. 1 2 3 4 Puente N, Cui Y, Lassalle O, Lafourcade M, Georges F, Venance L, Grandes P, Manzoni OJ (December 2011). "Polymodal activation of the endocannabinoid system in the extended amygdala". Nature Neuroscience. 14 (12): 1542–7. doi:10.1038/nn.2974. PMID   22057189. S2CID   2879731.
  31. ↑ Ibrahim BM, Abdel-Rahman AA (2014). "Cannabinoid receptor 1 signaling in cardiovascular regulating nuclei in the brainstem: A review". Journal of Advanced Research. 5 (2): 137–45. doi:10.1016/j.jare.2013.03.008. PMC   4294710 . PMID   25685481.
  32. ↑ Ibrahim BM, Abdel-Rahman AA (2015). "A pivotal role for enhanced brainstem Orexin receptor 1 signaling in the central cannabinoid receptor 1-mediated pressor response in conscious rats". Brain Research. 1622: 51–63. doi:10.1016/j.brainres.2015.06.011. PMC   4562882 . PMID   26096126. Orexin receptor 1 (OX1R) signaling is implicated in cannabinoid receptor 1 (CB1R) modulation of feeding. Further, our studies established the dependence of the central CB1R-mediated pressor response on neuronal nitric oxide synthase (nNOS) and extracellular signal-regulated kinase1/2 (ERK1/2) phosphorylation in the RVLM. We tested the novel hypothesis that brainstem orexin-A/OX1R signaling plays a pivotal role in the central CB1R-mediated pressor response. Our multiple labeling immunofluorescence findings revealed co-localization of CB1R, OX1R and the peptide orexin-A within the C1 area of the rostral ventrolateral medulla (RVLM). Activation of central CB1R ... in conscious rats caused significant increases in BP and orexin-A level in RVLM neuronal tissue. Additional studies established a causal role for orexin-A in the central CB1R-mediated pressor response
  33. ↑ Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N (February 2004). "Molecular characterization of a phospholipase D generating anandamide and its congeners". Journal of Biological Chemistry. 279 (7): 5298–305. doi: 10.1074/jbc.M306642200 . PMID   14634025.
  34. ↑ Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim HY, Kunos G (September 2006). "A biosynthetic pathway for anandamide". Proceedings of the National Academy of Sciences. 103 (36): 13345–50. Bibcode:2006PNAS..10313345L. doi: 10.1073/pnas.0601832103 . PMC   1557387 . PMID   16938887.
  35. ↑ Magotti P, Bauer I, Igarashi M, Babagoli M, Marotta R, Piomelli D, Garau G (2014). "Structure of Human N-Acylphosphatidylethanolamine-Hydrolyzing Phospholipase D: Regulation of Fatty Acid Ethanolamide Biosynthesis by Bile Acids". Structure. 23 (3): 598–604. doi:10.1016/j.str.2014.12.018. PMC   4351732 . PMID   25684574.
  36. ↑ Margheritis E, Castellani B, Magotti P, Peruzzi S, Romeo E, Natali F, Mostarda S, Gioiello A, Piomelli D, Garau G (2016). "Bile Acid Recognition by NAPE-PLD". ACS Chemical Biology. 11 (10): 2908–2914. doi:10.1021/acschembio.6b00624. PMC   5074845 . PMID   27571266.
  37. ↑ Leung D, Saghatelian A, Simon GM, Cravatt BF (April 2006). "Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids". Biochemistry. 45 (15): 4720–6. doi:10.1021/bi060163l. PMC   1538545 . PMID   16605240.
  38. ↑ Pazos MR, Núñez E, Benito C, Tolón RM, Romero J (June 2005). "Functional neuroanatomy of the endocannabinoid system". Pharmacology Biochemistry and Behavior. 81 (2): 239–47. doi:10.1016/j.pbb.2005.01.030. PMID   15936805. S2CID   12588731.
  39. ↑ Yamaguchi T, Shoyama Y, Watanabe S, Yamamoto T (January 2001). "Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats". Brain Research. 889 (1–2): 149–54. doi:10.1016/S0006-8993(00)03127-9. PMID   11166698. S2CID   34809694.
  40. ↑ Brock TG (December 2005). "Regulating leukotriene synthesis: the role of nuclear 5-lipoxygenase" (PDF). Journal of Cellular Biochemistry. 96 (6): 1203–11. doi: 10.1002/jcb.20662 . hdl:2027.42/49282. PMID   16215982. S2CID   18009424.
  41. ↑ Clapper JR, Mangieri RA, Piomelli D (2009). "The endocannabinoid system as a target for the treatment of cannabis dependence". Neuropharmacology. 56 (Suppl 1): 235–43. doi:10.1016/j.neuropharm.2008.07.018. PMC   2647947 . PMID   18691603.
  42. ↑ Kubrusly RC, Günter A, Sampaio L, Martins RS, Schitine CS, Trindade P, et al. (January 2018). "Neuro-glial cannabinoid receptors modulate signaling in the embryonic avian retina". Neurochemistry International. 112: 27–37. doi: 10.1016/j.neuint.2017.10.016 . PMID   29108864. S2CID   37166339.
  43. ↑ Galve-Roperh I, Rueda D, Gómez del Pulgar T, Velasco G, Guzmán M (December 2002). "Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor" (PDF). Molecular Pharmacology. 62 (6): 1385–92. doi:10.1124/mol.62.6.1385. PMID   12435806. S2CID   35655934. Archived from the original (PDF) on 28 February 2019.
  44. 1 2 Graham ES, Ball N, Scotter EL, Narayan P, Dragunow M, Glass M (September 2006). "Induction of Krox-24 by endogenous cannabinoid type 1 receptors in Neuro2A cells is mediated by the MEK-ERK MAPK pathway and is suppressed by the phosphatidylinositol 3-kinase pathway". The Journal of Biological Chemistry. 281 (39): 29085–95. doi: 10.1074/jbc.M602516200 . PMID   16864584.
  45. ↑ Kittler JT, Grigorenko EV, Clayton C, Zhuang SY, Bundey SC, Trower MM, Wallace D, Hampson R, Deadwyler S (September 2000). "Large-scale analysis of gene expression changes during acute and chronic exposure to [Delta]9-THC in rats" (PDF). Physiological Genomics. 3 (3): 175–85. doi:10.1152/physiolgenomics.2000.3.3.175. PMID   11015613. S2CID   25959929. Archived from the original (PDF) on 4 March 2019.
  46. ↑ Twitchell W, Brown S, Mackie K (1997). "Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons". Journal of Neurophysiology. 78 (1): 43–50. doi:10.1152/jn.1997.78.1.43. PMID   9242259.
  47. 1 2 Guo J, Ikeda SR (2004). "Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons". Molecular Pharmacology. 65 (3): 665–74. doi:10.1124/mol.65.3.665. PMID   14978245. S2CID   25065163.
  48. ↑ Binzen U, Greffrath W, Hennessy S, Bausen M, Saaler-Reinhardt S, Treede RD (2006). "Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons". Neuroscience. 142 (2): 527–39. doi:10.1016/j.neuroscience.2006.06.020. PMID   16889902. S2CID   11077423.
  49. ↑ Freund TF, Katona I, Piomelli D (2003). "Role of endogenous cannabinoids in synaptic signaling". Physiological Reviews. 83 (3): 1017–66. doi:10.1152/physrev.00004.2003. PMID   12843414.
  50. ↑ Chevaleyre V, Heifets BD, Kaeser PS, Südhof TC, Purpura DP, Castillo PE (2007). "Endocannabinoid-Mediated Long-Term Plasticity Requires cAMP/PKA Signaling and RIM1α". Neuron. 54 (5): 801–12. doi:10.1016/j.neuron.2007.05.020. PMC   2001295 . PMID   17553427.
  51. ↑ Bacci A, Huguenard JR, Prince DA (2004). "Long-lasting self-inhibition of neocortical interneurons mediated by endocannabinoids". Nature. 431 (7006): 312–6. Bibcode:2004Natur.431..312B. doi:10.1038/nature02913. PMID   15372034. S2CID   4373585.
  52. ↑ Hampson RE, Deadwyler SA (1999). "Cannabinoids, hippocampal function and memory". Life Sciences. 65 (6–7): 715–23. doi:10.1016/S0024-3205(99)00294-5. PMID   10462072.
  53. ↑ Pertwee RG (2001). "Cannabinoid receptors and pain". Progress in Neurobiology. 63 (5): 569–611. doi:10.1016/S0301-0082(00)00031-9. PMID   11164622. S2CID   25328510.
  54. 1 2 3 Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005). "Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects". Journal of Clinical Investigation. 115 (11): 3104–16. doi:10.1172/JCI25509. PMC   1253627 . PMID   16224541.
  55. 1 2 3 Aguado T, Monory K, Palazuelos J, Stella N, Cravatt B, Lutz B, Marsicano G, Kokaia Z, Guzmán M, Galve-Roperh I (2005). "The endocannabinoid system drives neural progenitor proliferation". The FASEB Journal. 19 (12): 1704–6. doi:10.1096/fj.05-3995fje. PMID   16037095. S2CID   42230.
  56. ↑ Christie BR, Cameron HA (2006). "Neurogenesis in the adult hippocampus". Hippocampus. 16 (3): 199–207. doi:10.1002/hipo.20151. PMID   16411231. S2CID   30561899.
  57. ↑ Gerdeman GL, Ronesi J, Lovinger DM (May 2002). "Postsynaptic endocannabinoid release is critical to long-term depression in the striatum". Nature Neuroscience. 5 (5): 446–51. doi:10.1038/nn832. PMID   11976704. S2CID   19803274.
  58. 1 2 Heifets BD, Castillo PE (12 February 2009). "Endocannabinoid signaling and long-term synaptic plasticity". Annual Review of Physiology. 71 (1): 283–306. doi:10.1146/annurev.physiol.010908.163149. PMC   4454279 . PMID   19575681.
  59. 1 2 Kirkham TC, Tucci SA (2006). "Endocannabinoids in appetite control and the treatment of obesity". CNS Neurol Disord Drug Targets. 5 (3): 272–92. doi:10.2174/187152706777452272. PMID   16787229.
  60. ↑ Di Marzo V, Sepe N, De Petrocellis L, Berger A, Crozier G, Fride E, Mechoulam R (December 1998). "Trick or treat from food endocannabinoids?". Nature. 396 (6712): 636–7. Bibcode:1998Natur.396..636D. doi:10.1038/25267. PMID   9872309. S2CID   4425760.
  61. ↑ De Luca MA, Solinas M, Bimpisidis Z, Goldberg SR, Di Chiara G (July 2012). "Cannabinoid facilitation of behavioral and biochemical hedonic taste responses". Neuropharmacology. 63 (1): 161–8. doi:10.1016/j.neuropharm.2011.10.018. PMC   3705914 . PMID   22063718.
  62. ↑ Yoshida R, et al. (January 2010). "Endocannabinoids selectively enhance sweet taste". Proceedings of the National Academy of Sciences. 107 (2): 935–9. Bibcode:2010PNAS..107..935Y. doi: 10.1073/pnas.0912048107 . JSTOR   40535875. PMC   2818929 . PMID   20080779.
  63. ↑ Bellocchio L, Cervino C, Pasquali R, Pagotto U (June 2008). "The endocannabinoid system and energy metabolism". Journal of Neuroendocrinology. 20 (6): 850–7. doi: 10.1111/j.1365-2826.2008.01728.x . PMID   18601709. S2CID   6338960.
  64. ↑ Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V (May 2010). "Endogenous cannabinoid signaling is essential for stress adaptation". Proceedings of the National Academy of Sciences. 107 (20): 9406–11. Bibcode:2010PNAS..107.9406H. doi: 10.1073/pnas.0914661107 . PMC   2889099 . PMID   20439721.
  65. ↑ Häring M, Kaiser N, Monory K, Lutz B (2011). Burgess HA (ed.). "Circuit specific functions of cannabinoid CB1 receptor in the balance of investigatory drive and exploration". PLOS ONE. 6 (11): e26617. Bibcode:2011PLoSO...626617H. doi: 10.1371/journal.pone.0026617 . PMC   3206034 . PMID   22069458.
  66. ↑ Basu S, Ray A, Dittel BN (December 2011). "Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses". The Journal of Immunology. 187 (11): 5720–32. doi:10.4049/jimmunol.1102195. PMC   3226756 . PMID   22048769.
  67. ↑ Maccarrone M, Valensise H, Bari M, Lazzarin N, Romanini C, Finazzi-Agrò A (2000). "Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage". Lancet. 355 (9212): 1326–9. doi:10.1016/S0140-6736(00)02115-2. PMID   10776746. S2CID   39733100.
  68. ↑ Das SK, Paria BC, Chakraborty I, Dey SK (1995). "Cannabinoid ligand-receptor signaling in the mouse uterus". Proceedings of the National Academy of Sciences. 92 (10): 4332–6. Bibcode:1995PNAS...92.4332D. doi: 10.1073/pnas.92.10.4332 . PMC   41938 . PMID   7753807.
  69. ↑ Paria BC, Das SK, Dey SK (1995). "The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling". Proceedings of the National Academy of Sciences. 92 (21): 9460–4. Bibcode:1995PNAS...92.9460P. doi: 10.1073/pnas.92.21.9460 . PMC   40821 . PMID   7568154.
  70. ↑ Hesselink JM (2012). "New Targets in Pain, Non-Neuronal Cells, and the Role of Palmitoylethanolamide". The Open Pain Journal. 5 (1): 12–23. doi: 10.2174/1876386301205010012 .
  71. ↑ Ghanem CI, Pérez MJ, Manautou JE, Mottino AD (July 2016). "Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity". Pharmacological Research. 109: 119–31. doi:10.1016/j.phrs.2016.02.020. PMC   4912877 . PMID   26921661.
  72. ↑ Colloca L (28 August 2013). Placebo and Pain: From Bench to Bedside (1st ed.). Elsevier Science. pp. 11–12. ISBN   978-0-12-397931-5.
  73. ↑ Ross RA (November 2003). "Anandamide and vanilloid TRPV1 receptors". British Journal of Pharmacology. 140 (5): 790–801. doi:10.1038/sj.bjp.0705467. PMC   1574087 . PMID   14517174.
  74. ↑ Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V (June 2002). "An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors". Proceedings of the National Academy of Sciences. 99 (12): 8400–5. Bibcode:2002PNAS...99.8400H. doi: 10.1073/pnas.122196999 . PMC   123079 . PMID   12060783.
  75. ↑ Murillo-Rodríguez E, Sánchez-Alavez M, Navarro L, Martínez-González D, Drucker-Colín R, Prospéro-García O (November 1998). "Anandamide modulates sleep and memory in rats". Brain Research. 812 (1–2): 270–4. doi:10.1016/S0006-8993(98)00969-X. PMID   9813364. S2CID   23668458.
  76. ↑ Santucci V, Storme JJ, Soubrié P, Le Fur G (1996). "Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis". Life Sciences. 58 (6): PL103–10. doi:10.1016/0024-3205(95)02319-4. PMID   8569415.
  77. ↑ Wang L, Yang T, Qian W, Hou X (January 2011). "The role of endocannabinoids in visceral hyposensitivity induced by rapid eye movement sleep deprivation in rats: regional differences". International Journal of Molecular Medicine. 27 (1): 119–26. doi: 10.3892/ijmm.2010.547 . PMID   21057766.
  78. ↑ Murillo-Rodriguez E, Désarnaud F, Prospéro-García O (May 2006). "Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat". Life Sciences. 79 (1): 30–7. doi:10.1016/j.lfs.2005.12.028. PMID   16434061.
  79. 1 2 3 Tantimonaco M, Ceci R, Sabatini S, Catani MV, Rossi A, Gasperi V, Maccarrone M (2014). "Physical activity and the endocannabinoid system: an overview". Cellular and Molecular Life Sciences. 71 (14): 2681–2698. doi:10.1007/s00018-014-1575-6. PMID   24526057. S2CID   14531019.
  80. 1 2 3 Raichlen DA, Foster AD, Gerdeman GL, Seillier A, Giuffrida A (2012). "Wired to run: exercise-induced endocannabinoid signaling in humans and cursorial mammals with implications for the 'runner's high'". Journal of Experimental Biology. 215 (Pt 8): 1331–1336. doi: 10.1242/jeb.063677 . PMID   22442371.
  81. ↑ Gachet MS, Schubert A, Calarco S, Boccard J, Gertsch J (January 2017). "Targeted metabolomics shows plasticity in the evolution of signaling lipids and uncovers old and new endocannabinoids in the plant kingdom". Scientific Reports. 7: 41177. Bibcode:2017NatSR...741177G. doi:10.1038/srep41177. PMC   5264637 . PMID   28120902.
  82. ↑ Wasternack C, Hause B (June 2013). "Jasmonates: biosynthesis, perception, signal transduction and action in plant stress response, growth and development. An update to the 2007 review in Annals of Botany". Annals of Botany. 111 (6): 1021–58. doi:10.1093/aob/mct067. PMC   3662512 . PMID   23558912.
  83. ↑ Hunter, E.; Stander, M.; Kossmann, J.; Chakraborty, S.; Prince, S.; Peters, S.; Loedolff, Bianke (2020). "Toward the identification of a phytocannabinoid-like compound in the flowers of a South African medicinal plant (Leonotis leonurus)". BMC Research Notes. 13 (1): 522. doi: 10.1186/s13104-020-05372-z . PMC   7653773 . PMID   33172494.
  84. ↑ Zhu, Hongkang; Hu, Bin; Hua, Hanyi; Liu, Chang; Cheng, Yuliang; Guo, Yahui; Yao, Weirong; Qian, He (2020). "Macamides: A review of structures, isolation, therapeutics and prospects". Food Research International. 138 (Pt B): 109819. doi:10.1016/j.foodres.2020.109819. PMID   33288191. S2CID   226344133.
  85. ↑ Mudge, Elizabeth; Lopes-Lutz, Daise; Brown, Paula; Schieber, Andreas (2011). "Analysis of Alkylamides in Echinacea Plant Materials and Dietary Supplements by Ultrafast Liquid Chromatography with Diode Array and Mass Spectrometric Detection". Journal of Agricultural and Food Chemistry. 59 (15): 8086–8094. doi:10.1021/jf201158k. PMID   21702479.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.